Cencora, Inc. (NYSE:COR) Stock Holdings Increased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC lifted its position in Cencora, Inc. (NYSE:COR) by 23.1% in the 3rd quarter, Holdings Channel.com reports. The fund owned 6,630 shares of the company’s stock after acquiring an additional 1,245 shares during the period. Sequoia Financial Advisors LLC’s holdings in Cencora were worth $1,492,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in COR. New Millennium Group LLC acquired a new position in Cencora in the second quarter worth $26,000. TCTC Holdings LLC acquired a new position in shares of Cencora in the 1st quarter valued at about $29,000. TFO Wealth Partners LLC bought a new stake in shares of Cencora during the 1st quarter valued at about $30,000. LRI Investments LLC acquired a new stake in Cencora during the first quarter worth about $31,000. Finally, MFA Wealth Advisors LLC bought a new position in Cencora in the second quarter worth about $30,000. 97.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

COR has been the subject of several recent research reports. Evercore ISI lowered their target price on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Robert W. Baird lowered their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research note on Friday, September 6th. Leerink Partners cut their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Bank of America reiterated a “neutral” rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $259.44.

Cencora Stock Up 0.3 %

Cencora stock opened at $235.17 on Friday. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66. The stock has a market cap of $46.91 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 1.40 and a beta of 0.44. The company’s 50-day moving average price is $232.22 and its two-hundred day moving average price is $230.91. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.92 earnings per share. On average, analysts expect that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a dividend of $0.51 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.87%. Cencora’s dividend payout ratio is currently 22.32%.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares in the company, valued at $2,656,970.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,461,153 shares of company stock valued at $1,073,075,720 over the last three months. Company insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.